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Blood-pressure targets in patients with recent lacunar stroke: 
the SPS3 randomised trial
The SPS3 Study Group*
Summary
Background Lowering of blood pressure prevents stroke but optimum target levels to prevent recurrent stroke are 
unknown. We investigated the eﬀ ects of diﬀ erent blood-pressure targets on the rate of recurrent stroke in patients 
with recent lacunar stroke. 
Methods In this randomised open-label trial, eligible patients lived in North America, Latin America, and Spain and 
had recent, MRI-deﬁ ned symptomatic lacunar infarctions. Patients were recruited between March, 2003, and April, 
2011, and randomly assigned, according to a two-by-two multifactorial design, to a systolic-blood-pressure target of 
130–149 mm Hg or less than 130 mm Hg. The primary endpoint was reduction in all stroke (including ischaemic 
strokes and intracranial haemorrhages). Analysis was done by intention to treat. This study is registered with 
ClinicalTrials.gov, number NCT 00059306. 
Findings 3020 enrolled patients, 1519 in the higher-target group and 1501 in the lower-target group, were followed up 
for a mean of 3·7 (SD 2·0) years. Mean age was 63 (SD 11) years. After 1 year, mean systolic blood pressure was 
138 mm Hg (95% CI 137–139) in the higher-target group and 127 mm Hg (95% CI 126–128) in the lower-target group. 
Non-signiﬁ cant rate reductions were seen for all stroke (hazard ratio 0·81, 95% CI 0·64–1·03, p=0·08), disabling or 
fatal stroke (0·81, 0·53–1·23, p=0·32), and the composite outcome of myocardial infarction or vascular death 
(0·84, 0·68–1·04, p=0·32) with the lower target. The rate of intracerebral haemorrhage was reduced signiﬁ cantly 
(0·37, 0·15–0·95, p=0·03). Treatment-related serious adverse events were infrequent. 
Interpretation Although the reduction in stroke was not signiﬁ cant, our results support that in patients with recent 
lacunar stroke, the use of a systolic-blood-pressure target of less than 130 mm Hg is likely to be beneﬁ cial.
Funding National Institutes of Health-National Institute of Neurological Disorders and Stroke (NIH-NINDS) 
Introduction 
Hypertension is the most relevant and prevalent risk 
factor for stroke, particularly for stroke associated with 
cerebral small-vessel disease. Reduction in blood pressure 
is the most eﬀ ective intervention to prevent stroke.1–3
Small subcortical brain infarcts, commonly known as 
lacunar strokes, comprise about 25% of ischaemic 
strokes.4,5 Most result from disease of the small 
penetrating arteries. Despite the frequency and 
importance of these strokes, randomised trials have not 
focused on prevention of recurrent stroke in patients 
with MRI-deﬁ ned lacunar stroke. Whether there are 
optimum blood-pressure targets to prevent stroke 
recurrence in patients with cerebral small-artery disease 
is unknown.6
In the Secondary Prevention of Small Subcortical 
Strokes (SPS3) trial we tested two interventions in 
patients with recent, symptomatic, MRI-conﬁ rmed 
lacunar stroke: two antiplatelet regimens and two target 
ranges of systolic blood pressure. The results of the 
antiplatelet component have been published previously.7 
We present here the results of the blood-pressure 
component of the trial, in which we tested the hypothesis 
that assignment to a lower target range for systolic blood 
pressure would lessen the rate of stroke recurrence 
compared with a higher target range.
Methods
Patients 
Details of the rationale, study design, and characteristics 
of the participants in SPS3 have been described 
elsewhere.8,9 Brieﬂ y, SPS3 was a randomised, multicentre, 
clinical trial undertaken in 81 centres in North America, 
Latin America, and Spain between March, 2003, and 
April, 2011. Eligible patients were aged 30 years or older, 
were normotensive or hypertensive, had had a recent 
(within 180 days), symptomatic, MRI-conﬁ rmed lacunar 
stroke, and were without surgically amenable ipsilateral 
carotid artery stenosis or high-risk cardioembolic 
sources. Main exclusion criteria included disabling 
stroke (modiﬁ ed Rankin score of 4 or higher), previous 
intracranial haemorrhage from non-traumatic causes, or 
cortical ischaemic stroke.7,8 Participation required written 
informed consent and approval was provided by local 
ethics committees for human research.
Randomisation and masking
Patients were randomised, according to a two-by-two 
factorial design, to two blood-pressure-control groups 
with targets of 130–149 mm Hg or less than 130 mm Hg.10 
Treatment was open label. To avoid lowering of blood 
pressure soon after an acute stroke, participants were 
randomised at least 2 weeks after the index stroke. 
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Randomisation was stratiﬁ ed by clinical centre and 
baseline hypertensive status. The schedule was computer 
generated with a permuted-block design (variable block 
size). Treatment assignments were stored electronically 
on the study servers at the SPS3 statistical centre, 
University of Alabama at Birmingham, AL, USA, as well 
as locally for each study site on an SPS3-designated 
computer. Upon patients’ eligibility being established, 
study coordinators ransomised patients via their data 
entry systems.
Management of blood pressure
Baseline hypertensive status was determined by measure-
ment of blood pressure taken at two consecutive visits 
before randomisation. Patients taking medications to 
control blood pressure were allowed to continue doing so. 
Blood pressure was measured three times at every visit 
and the average measurement was used to decide hyper-
tensive status.8−11 Patients were classiﬁ ed as being hyper-
tensive if either or both of the following features were 
noted: average systolic blood pressure 140 mm Hg or 
higher or diastolic blood pressure 90 mm Hg or higher on 
two consecutive visits, and conﬁ rmed history of hyper-
tension before the index stroke and taking antihypertensive 
medication at the time of visit. After randomisation, if 
patients had blood pressures outside the assigned 
target range, they were initially seen at least monthly for 
measurement of blood pressure and adjustment of 
medications. Patients whose blood pressure was in the 
relevant range for two consecutive visits were seen every 
3 months. If at any point during the study a patient’s 
systolic blood pressure was outside the assigned target 
range, he or she was asked to return within 1 month.  
All study sites were provided with automated 
Colin Press-Mate BP-8800C sphygmomanometers (Colin 
Medical Instruments, San Antonio, TX, USA).11 Blood-
pressure management was overseen at each site by a 
physician with special expertise in blood-pressure 
control. If systolic blood pressure in patients assigned to 
the higher-target group (130–149 mm Hg) dropped to 
below the lower limit of the target range, the protocol 
required that patients taking antihypertensive medi-
cations stop taking them or have the doses reduced, 
unless prescribed for reasons other than blood pressure 
control; patients taking no antihypertensive medications 
continued to be followed up every 3 months. If systolic 
blood pressure increased to within the target range, 
patients were managed according to their originally 
assigned target. If patients or primary-care physicians 
refused to titrate blood pressure to the assigned target 
range per protocol, patients were classiﬁ ed as inactive. 
Patients whose blood pressure could not be kept within 
the assigned target range for medical reasons or because 
of intolerable side-eﬀ ects of antihypertensive drugs after 
trying diﬀ erent agents were classiﬁ ed as failure to achieve 
assigned target. All participants were followed up to a 
common end-of-study date, irrespective of activity status.
Antihypertensive medications were prescribed by the 
local study physician and supplied via the study formu-
laries. At least one drug from each of the major classes of 
Higher-target 
group 
(n=1519)
Lower-target 
group 
(n=1501)
Age (years) 63 (10·8) 63 (10·7)
Men 990 (65%) 912 (61%)
Blood pressure at entry (mm Hg)
Systolic 144 (19) 142 (19)
Diastolic 79 (11) 78 (10)
Body-mass index (kg/m2) 29·2 (7·5) 29·0 (6·1)
History of hypertension 1137 (75%) 1127 (75%)
Diabetes mellitus 553 (36%) 553 (37%)
Ischaemic heart disease 173 (11%) 144 (10%)
Previous clinical stroke or TIA 211 (14%) 237 (16%)
Current tobacco smoker 308 (20%) 309 (21%)
Qualifying event
Ischaemic stroke 1506 (99%) 1473 (98%)
TIA 13 (1%) 28 (2%)
Ethnic origin
White 760 (50%) 778 (52%)
Hispanic 468 (31%) 448 (30%)
Black 251 (17%) 241 (16%)
Other 40 (3%) 34 (2%)
Region
North America 987 (65%) 976 (65%)
Latin America 352 (23%) 342 (23%)
Spain 183 (12%) 183 (12%)
Number of antihypertensive 
medications at study entry 
1·7 (1·2) 1·7 (1·2)
Mean number of antihypertensive 
medications at 1 year*
1·8 (1·4) 2·4 (1·3)
Types of antihypertensive medications at 1 year†
Thiazides 576 (43%) 774 (58%)
ACE inhibitor/ARB 835 (63%) 1064 (80%)
Calcium-channel blockers 398 (30%) 571 (43%)
β blockers 333 (25%) 408 (31%)
Other 117 (9%) 146 (11%)
Mean number of antihypertensive 
medication at last visit‡
1·8 (1·4) 2·4 (1·4)
Types of antihypertensive medications at last visit§
Thiazides 569 (38%) 804 (54%)
ACE inhibitor/ARB 894 (60%) 1156 (78%)
Calcium-channel blockers 438 (39%) 637 (43%)
β blockers 424 (28%) 521 (35%)
Other 168 (11%) 204 (14%)
Statins used during follow-up 1248 (84%) 1254 (85%)
Data are mean (SD) or number (%). TIA=transient ischaemic attack. 
ACE=angiotensin-converting enzyme. ARB=antiotensin-II-receptor 
blocker.*Diﬀ erence between groups p<0·0001. †Diﬀ erence between groups 
p<0·0001 for all types, except β blockers (p=0·0008) and other (p=0·051). 
‡Diﬀ erence between groups p<0·0001. §Diﬀ erence between groups p<0·0001 for 
all types, except other (p=0·042). 
Table 1: Patients’ characteristics 
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antihypertensive medications was available. They were 
obtained and distributed to study centres by the Veterans 
Administration Cooperative Studies Pro gram Clinical 
Research Coordinating Center, Drug Distribution Center, 
Albuquerque, NM, USA.
 Statistical analysis
The primary endpoint was reduction in all stroke. 
Ischaemic stroke was clinically deﬁ ned as a focal neuro-
logical deﬁ cit persisting for longer than 24 h, with an 
absence of haemorrhage conﬁ rmed by neuroimaging. 
Intracranial haemorrhages included intracerebral, sub-
dural or epidural, and subarachnoid locations deﬁ ned by 
neuroimaging. Disabling strokes were classi ﬁ ed as those 
with modiﬁ ed Rankin scores of 3 or higher after 
3–6 months. Strokes were deemed fatal if death occurred 
within 30 days or if death after 30 days could be attributed 
to the stroke. Secondary endpoints were reductions in 
acute myocardial infarction, deﬁ ned by standard criteria 
(compatible clinical history with changes on ECG or in 
cardiac enzyme concentrations), need for acute admis-
sion to hospital for a major vascular event, and death, 
classiﬁ ed as vascular, non-vascular, or unknown. All 
reported eﬃ  cacy outcomes were con ﬁ rmed by a central 
adjudication committee that was unaware of treatment 
assignment. Safety outcomes were serious adverse events 
related to hypotension and blood-pressure management. 
The trial was monitored by an independent data and 
safety monitoring committee selected by the sponsor.
The initial sample size of 2500 patients was calculated 
assuming an average follow-up of 3 years, an estimated 
3-year recurrent stroke rate of 21%, a 25% relative-risk 
reduction in stroke by intensive control of blood pressure, 
a type I error of α=0·05, and 90% power. Sample-size 
estimation was reassessed midway through the trial to 
check the power of the study on the basis of the observed 
overall event rate. This assessment resulted in the ﬁ nal 
sample size being increased from 2500 to 3000 patients.12 
We did two prespeciﬁ ed subgroup analyses. The ﬁ rst 
was in patients who were hypertensive at baseline. Thus, 
we excluded from this analysis patients who were non-
hypertensive at baseline (systolic blood pressure lower 
than 130 mm Hg without taking antihypertensive medi-
cations) and who received no antihypertensive therapy 
during the study unless blood pressure exceeded the 
assigned target range during follow-up. The second 
included data after censoring at 6 months of follow-up. 
This analysis was undertaken because the maximum 
separation of the baseline and achieved blood pressures 
requires an average of 6 months of medication titration. 
All participants who did not die or withdraw from the 
study during the ﬁ rst 6 months, irrespective of whether 
or not they had an event during this time, were included 
in this subgroup. We also assessed outcomes in various 
demographic and clinical subgroups. 
We did standard time-to-event analyses of the pri-
mary endpoint with the log-rank test and used Cox’s 
proportional hazards models to compute hazard ratios 
(HRs) and 95% CIs in each treatment group. If multiple 
events of the same type occurred, time to event was 
calculated as time to ﬁ rst event. Data for patients with no 
Higher-target group 
(n=1519)
Lower-target group 
(n=1501)
Hazard ratio 
(95% CI)
p value
Number of 
patients
Rate (% per 
patient-year)
Number of 
patients
Rate (% per 
patient-year)
Stroke
All stroke 152 2·77% 125 2·25% 0·81 
(0·64–1·03)
0·08
Ischaemic stroke 
or unknown
131 2·4% 112 2·0% 0·84 
(0·66–1·09)
0·19
Intracranial haemorrhage
All 21* 0·38% 13† 0·23% 0·61 
(0·31–1·22)
0·16
Intracerebral 16 0·29% 6 0·11% 0·37 
(0·15–0·95)
0·03
Subdural or 
epidural
5 0·091% 6 0·11% 1·18 
(0·36–3·88)
0·78
Other 2 0·036% 4 0·072% 1·97 
(0·36–10·74)
0·43
Disabling or fatal 
stroke‡
49 0·89% 40 0·72% 0·81 
(0·53–1·23)
0·32
Myocardial infarction 40 0·70% 36 0·62% 0·88 
(0·56–1·39)
0·59
Major vascular event* 188 3·46% 160 2·91% 0·84 
(0·68–1·04)
0·10
Deaths
All 101 1·74% 106 1·80% 1·03 
(0·79–1·35)
0·82
Vascular death 41 0·70% 36 0·61% 0·86 
(0·55–1·35)
0·52
Non-vascular 35 0·60% 40 0·68% 1·12 
(0·71–1·76)
0·62
Uncertain 25 0·43% 30 0·51% 1·18 
(0·69–2·00)
0·55
*One classiﬁ ed as both intracerebral and other, and one as both intracerebral and subdural or epidural. †One classiﬁ ed 
as intracerebral and subdural or epidural, and two as both intracerebral and other. ‡Disabling strokes classiﬁ ed as 
modiﬁ ed Rankin score 3 or higher after 3–6 months.
Table 2: Primary and secondary outcomes
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Figure 1: Systolic blood pressure by treatment group
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events were censored at the end of study participation 
or death, whichever occurred ﬁ rst. The proportional 
hazards assumption was veriﬁ ed by assessment of the 
interaction between time and blood-pressure-inter-
vention group, and we used Cox’s models to investigate 
whether the eﬀ ect of intervention diﬀ ered by speciﬁ c 
subgroups. Odds ratios and 95% CIs were computed by 
logistic regression for orthostatic symptoms, as these 
were measured as whether or not the patient had at least 
one symptom during the follow-up period All analyses 
were based on the intention-to-treat principle and were 
done with SAS (version 9.2). The study is registered with 
ClinicalTrials.gov, number NCT00059306.
Role of the funding source
The sponsor of the study participated in study design, 
data collection, data analysis, data interpretation, and 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
3020 participants were enrolled from North America 
(n=1960 [65%]), Latin America (n=694 [23%]), and Spain 
(n=366 [12%]) and were followed up for a mean of 
3·7 (range 0–8·6, SD 2·0) years (appendix p 1). Baseline 
characteristics did not diﬀ er substantially between target 
groups (table 1). The median time from qualifying stroke 
to randomisation was 62 days. Blood-pressure therapy 
was permanently discontinued in similar numbers of 
Number at risk
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0
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1501
1
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HR 0·81 (95% CI 0·64–1·03)
Number of events (annualised rate [%])
130–149 mm Hg
Subgroup (pinteraction) HR (95% CI)
<130 mm Hg
Age (p=0·53)
<65 years (n=1757)
≥65 years (n=1263)
Sex (p=0·50)
Male (n=1902)
Female (n=1118)
History of diabetes (p=0·64)
Non-diabetic (n=1914)
Diabetes (n=1106)
Race (p=0·85)
Hispanic (n=916)
White (n=1538)
Black (n=492)
Other/mixed (n=74)
Region of residence (p=0·09)
North America (n=1960)
Latin America (n=694)
Spain (n=366)
Baseline SBP (p=0·78)
Normotensive (n=314)
SBP<median (n=1306)
SBP≥median (n=400)
 87 (2·71%)
 67 (2·86%)
 111 (3·09%)
 41 (2·17%)
 78 (2·15%)
 74 (3·97%)
 36 (2·23%)
 72 (2·56%)
 37 (4·09%)
 7 (4·53%)
 111 (2·90%)
 24 (2·11%)
 17 (3·31%)
 11 (2·03%)
 65 (2·90%)
 76 (2·81%)
 68 (2·05%)
 57 (2·53%)
 80 (2·41%)
 45 (2·01%)
 59 (1·64%)
 66 (3·37%)
 29 (1·83%)
 63 (2·22%)
 30 (3·04%)
 3 (2·11%)
 100 (2·58%)
 20 (1·77%)
 5 (0·92%)
 12 (2·03%)
 53 (2·18%)
 60 (2·36%)
0·76 (0·55–1·05)
0·89 (0·62–1·26)
0·78 (0·59–1·04)
0·93 (0·61–1·43)
0·76 (0·54–1·07)
0·85 (0·61–1·19)
0·82 (0·51–1·34)
0·86 (0·62–1·21)
0·75 (0·47–1·22)
0·48 (0·12–1·85)
0·89 (0·68–1·17)
0·84 (0·47–1·52)
0·28 (0·10–0·76)
1·02 (0·45–2·31)
0·75 (0·20–1·08
0·84 (0·60–1·18)
<130 mm Hg better 130–149 mm Hg better
1·00·5 2·00·2 5·0
Figure 2: Probability of patients experiencing a primary event by time after randomisation
Primary events were all recurrent strokes, myocardial infarction, or vascular death. HR=hazard ratio.
Figure 3: Primary outcome assessed by demographic and clinical subgroups
HR=hazard ratio. SBP=systolic blood pressure.
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patients in the higher-target and lower-target groups 
(258 [17%] vs 240 [16%]). 90 (3%) participants were lost to 
follow-up and an additional 465 (15%) ended follow-up 
early for the following reasons: withdrawn consent 
(n=242), site closure (n=151), physician request (n=12), 
and other reasons (n=60).
At 1 year of follow up, the achieved average systolic 
blood pressures were 138 mm Hg (95% CI 137–139) in 
the higher-target group and 127 mm Hg (126–128) in the 
lower-target group, with 1139 (75%) and 976 (65%), 
respectively, having blood pressures within the assigned 
target ranges. At the last study visit, the mean diﬀ erence 
in systolic blood pressures between the two groups was 
11 mm Hg (SD 16, ﬁ gure 1, appendix p 2). At 1 year, 
patients in the lower-target group had received a greater 
mean number of antihypertensive drugs than had those 
in the higher-target group (table 1). 
During follow-up, 277 ﬁ rst recurrent strokes occurred. 
Of these, 243 (86%) were ischaemic (of which 
173 [71%] were recurrent lacunar strokes) and 34 (14%) were 
intracranial haemorrhages. The annualised rate of 
recurrent stroke among those assigned to the higher-
target group was 2·77%, as compared with 2·25% in the 
lower-target group (hazard ratio 0·81, 95% CI 0·64–1·03; 
p=0·08; table 2, ﬁ gure 2). A similar result was seen for 
disabling or fatal stroke (table 2). The rate of intracerebral 
haemorrhage was signiﬁ cantly reduced in the lower-target 
group, whereas mortality was nearly identical (table 2). A 
13% reduction in the rate of recurrent lacunar strokes was 
seen in the lower-target group (HR 0·87, 95% CI 
0·62–1·22, p=0·41). There was no heterogeneity in treat-
ment eﬀ ect on the primary outcome in any of the 
demographic or clinical subgroups (ﬁ gure 3).
In the prespeciﬁ ed subgroup analysis restricted to the 
2706 participants classiﬁ ed as hypertensive at study entry, a 
20% reduction in recurrent stroke was seen in the lower-
target group (appendix p 3). Censoring of the ﬁ rst 6 months 
of follow-up in all participants showed a nearly identical 
rate reduction for recurrent stroke (appendix p 3). 
Although few serious adverse events related to hypo-
tension were noted, they were more frequent in the lower-
target group than in the higher-target group, but not 
signiﬁ cantly so (table 3). Syncope was the most frequent 
event but did not result in permanent sequelae. Symp-
toms potentially related to blood-pressure management 
were similar in the two groups (table 4).
Discussion
Lowering of systolic blood pressure to a target of less than 
130 mm Hg in patients with recent lacunar stroke resulted 
in non-signiﬁ cant reductions in all stroke, disabling or 
fatal stroke, and major vascular events, and a signiﬁ cant 
reduction in intracerebral stroke. These eﬀ ects were 
associated with few serious side-eﬀ ects, and were con-
sistent across major subgroups, including patients with 
diabetes and Hispanic patients, and irrespective of blood 
pressure at study entry. Exclusion of normotensive 
patients at entry showed a reduction in the rate of 
recurrent stroke of 20% in the lower–target group, 
although this reduction was not signiﬁ cant. Blood-
pressure lowering oﬀ ered a similar eﬀ ect on stroke 
recurrence irrespective of stroke subtype (table 5, ﬁ gure 4).
That lower is better is a general construct for chronic 
blood-pressure management after stroke, but optimum 
clinical practice requires that beneﬁ ts and risks associated 
with speciﬁ c targets be deﬁ ned. The PROGRESS trial2 
showed that lowering of blood pressure in stroke 
survivors was associated with a reduction of 28% in 
stroke recurrence. The mean achieved systolic blood 
pressure at the end of the study was 138 mm Hg, but the 
optimum target for blood-pressure control was not 
established. Similarly to the ACCORD trial,19 we explored 
the eﬃ  cacy and safety of setting systolic-blood-pressure 
targets lower than 130 mm Hg, but our assessment was 
extended to patients with MRI-deﬁ ned lacunar stroke 
attributed to small-vessel disease. 
Our results are best viewed in the context of previous 
trials of long-term lowering of blood pressure in patients 
who have had brain ischaemia (table 5, ﬁ gure 4).1–3,13–17,20 
We tested target blood pressure rather than speciﬁ c 
antihypertensive agents and explored eﬀ ects in patients 
with well deﬁ ned ischaemic-stroke subtypes. Although 
the magnitude of the reduction in rate was not 
signiﬁ cant, the ﬁ ndings are strongly supported by those 
of previous trials.1–3
Higher-target group 
(n=1519)
Lower-target group 
(n=1501)
Hazard ratio 
(95% CI)
p value
Number of 
patients
Rate (% per 
patient-year)
Number 
of patients
Rate (% per 
patient-year)
All 15 0·26 23 0·40 1·53 
(0·80–2·93)
0·20
Orthostatic syncope 5 0·09 11 0·19 2·18 
(0·76–6·27)
0·14
Stroke associated with 
hypotension
1 0·02 2 0·03 2·00 
(0·18–22·09) 
0·57
Myocardial infarction 0 0 0 0 NA NA
Fall with injury 0 0 3 0·052 NA NA
Other 11 0·19 9 0·15 0·82 
(0·34–1·97)
0·65
NA=not applicable.
Table 3: Serious adverse events related to hypotension 
Higher-target group 
(n=1519)
Lower-target group 
(n=1501)
Odds ratio 
(95% CI)
p value
Unsteadiness when standing 355 (24%) 375 (26%) 1·09 (0·92–1·29) 0·31
Blurred vision when standing 103 (7%) 85 (6%) 0·82 (0·61–1·11) 0·19
Dizziness when standing up 304 (21%) 324 (22%) 1·10 (0·92–1·31) 0·30
Light-headedness when 
standing
236 (16%) 222 (15%) 0·94 (0·77–1·15) 0·54
Palpitations when standing 24 (0·4%) 21 (0·4%) 0·86 (0·48–1·55) 0·62
Table 4: Side-eﬀ ects potentially related to blood-pressure management 
See Online for appendix
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The trial protocol was based on the assigned target of 
systolic blood pressure being achieved and, therefore, we 
did not require speciﬁ c antihypertensive agents to be 
used. Patients assigned to the lower-target group used an 
average of 2·4 antihypertensive medications and the 
distribution of medication categories diﬀ ered from that 
in the higher-target group (table 1). The mean diﬀ erence 
in systolic blood pressure at the end of the trial was 
11 mm Hg. On the basis of previous studies, this 
diﬀ erence should have resulted in about a 30% reduction 
in recurrent stroke. The observed reduction of 19% 
(95% CI –3 to 36), however, was smaller even than the 
hypothesised 25%. This ﬁ nding could be due to chance or 
the speciﬁ c population of patients assessed.2,21 The 95% CI 
for the 19% reduction does include the hypothesised 25% 
reduction, but it also spans zero and, therefore, is not 
signiﬁ cant. The rate of intracerebral haemorrhage was 
reduced by 63% in the lower-target group, which is 
consistent with the known sensitivity of this stroke sub-
type to strict blood-pressure control.14 This result indicates 
that the number needed to treat to prevent one intra-
cerebral haemorrhage at 4 years (roughly the average 
follow-up in SPS3) would be 175.
The SPS3 trial had limitations. First, the observed rate 
of recurrent stroke was much lower than that 
anticipated. This low rate is similar to that seen in other 
trials that have assessed prevention of recurrent 
stroke.22–24 It might, therefore, be the result of good 
blood-pressure control in both treatment groups, the 
frequent use of statins, and high adherence to 
antiplatelet therapy. Second, the assign ment to blood-
pressure targets was not masked, which could have 
potentially introduced bias. Stroke end points were, 
however, conﬁ rmed by a central adjudication committee 
that was unaware of patients’ group allo cations, as is 
frequently done in large hyper tension trials.25 Third, we 
tested treatment targets and not the eﬀ ect of speciﬁ c 
blood-pressure agents. Finally, some patients did not 
achieve blood pressures within the target ranges at any 
point during follow-up (70 [4·6%] in the higher-target 
group and 74 [4·9%] in the lower-target group). These 
proportions, however, are similar to those reported in 
other trials of blood-pressure targets and, therefore, 
probably reﬂ ect the clinical realities of blood-pressure 
management.19,25 An important strength of the SPS3 
Intervention Population (mean follow-up) Number of 
patients
Achieved systolic blood 
pressure (diﬀ erence 
between treated patients 
and controls [mm Hg])
Relative risk 
reduction for 
recurrent stroke 
(95% CI)
HSCSG (1974)13 Deserpidine, thiazide Heterogeneous stroke, uncertain ischaemic 
(96%) vs ICH (2·3 years)
452 ~167 vs ~142 (25) 20%† (–29 to 51) 
Dutch TIA (1993)14 Atenolol All causes of TIA (34%) or ischaemic stroke 
(2·6 years)
1473 ~155 vs ~149 (6) 18% (–19 to 43)
PATS (1995)15 Indapamide Heterogeneous, including TIA (12%) and ICH 
(14%; 2·0 years)
5665 149 vs 144 (5) 29% (12 to 41)
TEST (1995)16 Atenolol Heterogeneous ischaemic stroke (2·3 years) 720 161 vs 157 (4) 0% (–45 to 30)
INDANA (1997)1 Multiple Subgroups with previous stroke from ﬁ ve 
hypertension trials (NR)
519 NR 29% (–14 to 56)
HOPE (2000)17‡ Ramipril Heterogeneous (NR) 1013 ~151 vs ~141 (10) 15% (–30 to 44)
PROGRESS (2001)2 Perindopril, 
indapamide
Heterogeneous, including TIA (22%) and ICH 
(11%; 3·9 years)§
6105 ~144 vs ~135 (9) 28% (17 to 38)
PRoFESS (2008)15 Telmisartan All causes of ischaemic stroke, including small-
artery disease (52%; 2·5 years)
20 322 ~141 vs ~137 (4) 5% (–4 to 14)
SPS3 (2013) Target systolic-blood-
pressure levels*
MRI-proven recent lacunar infarction (3·6 years) 3020 138 vs 127 (11) 19% (–3 to 36)
ICH=intracerebral haemorrhage. TIA=transient ischemic attack. NR=not reported. *No trials other than SPS3 tested target blood-pressure levels, although the MOSES trial 
compared eprosartan with nitrendipine in stroke survivors, but only a small diﬀ erence (1·5 mm Hg) was achieved in systolic blood pressure in a small number of participants 
and, therefore, did not reliably characterise blood-pressure eﬀ ects.18 †Relative-risk reduction computed as 1–odds ratio because not reported in publication. ‡HOPE results for 
patients with previous stroke or TIA are presented in ﬁ gure 2a of Rashid and colleagues,3 but are otherwise unpublished.§Analysis restricted to patients with ischaemic stroke 
as the qualifying events showed a 26% (95% CI 12–36) reduction in subsequent strokes.2
Table 5: Randomised trials of long-term blood-pressure lowering in patients with stroke or TIA*
HSCSG
Dutch TIA
PATS
TEST
INDANA
HOPE
PROGRESS
PRoFESS
SPS3
0–60 604020–40 –20
Relative-risk reduction (95% CI) for recurrent stroke (%)
Figure 4: Randomised trials of long-term blood-pressure lowering for 
secondary stroke prevention
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trial is that blood-pressure lowering was tested in a well 
deﬁ ned and homogeneous cohort of stroke patients. 
In conclusion, although our results do not show a 
signiﬁ cant reduction in the rate of recurrent stroke, the 
ﬁ ndings are congruent with those of previous trials of 
blood-pressure lowering after stroke and support a 
treatment target of less than 130 mm Hg systolic blood 
pressure for most patients with recent lacunar stroke 
(panel). As our study cohort comprised patients with 
recent lacunar strokes due mainly to cerebral small-
vessel disease, whether our ﬁ ndings are applicable to 
patients with strokes from other mechanisms warrants 
additional research. 
The SPS3 study group 
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Winston-Salem, NC, n=29); D Tirschwell, C Logar, M Ryan, G Schubert, 
P Tanzai (University of Washington, Seattle, WA, n=27); T Mirsen, 
S McAllister, A Bastien, P Niblack, (Cooper Health System Dept of 
Medicine, Camden, NJ, n=26); J Frey, C Darbonne (St Joseph’s Hospital 
and Medical Center, Phoenix, AZ, n=25); P Karanjia, N Murali, R Dart, 
K Mancl (Marshﬁ eld Clinic Department of Neurology, Marshﬁ eld, WI, 
n=24); R Atkinson, R Lieberman, T Carter, P Zrelak, N Kenney (Sutter 
Neuroscience Institute, Sacramento, CA, n=22); M Jacoby, D Jones, 
J DeFrancisco, T Hamm (Ruan Neurology Clinic and Research Center, 
Des Moines, IA, n=21); J Romano, G Ortiz, M del Carmen Lichtenberger 
(University of Miami, Miller School, Miami, FL, n=17); R Linas, S Kravet, 
J Alt (Johns Hopkins Bayview, Baltimore, MD, n=16); S Sundararajan, 
M Rahman, T Horvath, D Korosec, C Murphy (University Hospitals Case 
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J Newgent, J Naylor, L Carpenter (Washington University in St Louis, 
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C Fanale, L Neeper, P Fisk (Colorado Neurological Institute, Denver, CO, 
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Sunrise, Las Vegas, NV, n=1); D Tong, M Garcia (Stanford University, 
Stanford, CA, n=1). Canada A Mackey, J Morin, A Haché, C Lessard 
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L Green, L Wadup, A-M Fontaine (McGill University−Montreal General, 
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Panel: Research in context
Systematic review
We searched PubMed and Cochrane Library for randomised 
clinical trials of secondary stroke prevention with blood-
pressure reduction as an intervention, published before April, 
2013, in all languages. We used the search terms “blood 
pressure”, “reduction”, hypertension”, “secondary”, “stroke”, 
“prevention”, and “clinical trial”. Eight randomised clinical 
trials2,13−18 and one pooled analysis1  were identiﬁ ed. Aggregate 
results showed consistently that reduced blood pressure in 
stroke survivors lessened the risk of stroke recurrence. 
Interpretation
We assessed blood-pressure targets in survivors of MRI-deﬁ ned 
lacunar stroke. A reduced rate of all stroke was observed in 
patients with a target systolic blood pressure lower than 
130 mm Hg compared with a target of 130–149 mm Hg, but 
this diﬀ erence was not signiﬁ cant. The intervention was safe 
and well tolerated. Interpreted in the context of previous 
randomised, controlled trials of blood-pressure lowering after 
stroke, our results suggest that management of systolic to 
levels lower than 130 mm Hg is likely to reduce the risk of 
recurrent stroke in patients with recent lacunar stroke.
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